

Ontario Public Drug Programs

Drug Submission Status
Updated: August 22, 2014

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Ranbaxy Canada Inc.	Ran-Memantine	Ebixa	memantine HCl	10mg	tablet	02421364
Mint Inc.	Mint-Hydrochlorothiazide	Pms-Hydrochlorothiazide	hydrochlorothiazide	12.5mg	tablet	02425947
PMS Inc.	Pms-Olanzapine ODT	Zyprexa Zydis	olanzapine	20mg	ODT tablet	02423944
Teva Canada Limited	Teva-Modafinil	Alertec	modafinil	100mg	tablet	02420260
Dr. Reddy's Laboratories Canada Inc.	Zoledronic Acid for Injection Concentrate	Zometa Concentrate	zoledronic acid monohydrate	4mg/5mL	IV solution	02422425